Rabbit Polyclonal IGF2 Antibody

The insulin-like growth factor 2 (IGF2) is a peptide hormone crucial for fetal growth, metabolism, and cellular proliferation. It primarily binds to the insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (IR-A isoform), activating downstream signaling pathways like PI3K/AKT and MAPK. Dysregulation of IGF2. often due to loss of imprinting or overexpression, is implicated in cancers, metabolic disorders, and developmental syndromes (e.g., Beckwith-Wiedemann syndrome). IGF2 antibodies are research and therapeutic tools designed to target IGF2 or its signaling pathways. In research, they are used to study IGF2's role in diseases via techniques like immunohistochemistry, Western blotting, or blocking ligand-receptor interactions. Therapeutically, anti-IGF2 antibodies aim to inhibit tumor progression by disrupting IGF2-driven proliferation and survival signals. Challenges include minimizing cross-reactivity with IGF1 due to structural homology and optimizing specificity. Recent studies explore bispecific antibodies or combination therapies to enhance efficacy. While clinical applications remain experimental, preclinical models show promise in cancers with IGF2/IGF1R axis dependency. Further research focuses on biomarker identification to stratify patients likely to benefit from IGF2-targeted therapies.